Feb 26, 2026 12:20PM
Feb 26, 2026 11:52AM
Feb 27, 2025 05:37PM
Nov 1, 2024 07:22AM
Jun 24, 2024 05:46AM
May 9, 2024 12:12PM
Apr 16, 2024 01:00AM argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Mar 5, 2024 11:14AM
Feb 20, 2024 03:10AM
Feb 20, 2024 01:00AM
Mar 2, 2023 01:00AM
Jan 27, 2023 01:00AM
Jan 9, 2023 04:53AM
Jan 9, 2023 01:00AM argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
Nov 22, 2022 01:00AM
Dec 20, 2021 06:07AM
Oct 28, 2021 02:37PM
Oct 28, 2021 01:00AM
Oct 6, 2021 04:16PM
Aug 25, 2021 06:28AM
Aug 25, 2021 01:00AM argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
Jul 29, 2021 01:00AM
Jun 17, 2021 06:09AM
Jun 16, 2021 06:30PM
May 17, 2021 06:51AM
May 14, 2021 01:00AM
Mar 9, 2021 07:48AM
Mar 4, 2021 01:00AM argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
Mar 2, 2021 02:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All